LESCOL XL DIN 02250527
Status: Cancelled Post Market
Holder: NOVARTIS PHARMACEUTICALS CANADA INC
Molecule: FLUVASTATIN (FLUVASTATIN SODIUM)
Health Canada record
| Active ingredient(s) | FLUVASTATIN (FLUVASTATIN SODIUM) 80 MG |
|---|---|
| Dosage form | Tablet (Extended-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | C10AA04 FLUVASTATIN |
| Original market date | 05-Apr-2004 |
| Current status date | 14-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FLUVASTATIN (FLUVASTATIN SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02299232 | TEVA-FLUVASTATIN | TEVA CANADA LIMITED | Capsule | FLUVASTATIN (FLUVASTATIN SODIUM) 40 MG | Marketed |
| 02299224 | TEVA-FLUVASTATIN | TEVA CANADA LIMITED | Capsule | FLUVASTATIN (FLUVASTATIN SODIUM) 20 MG | Marketed |
| 02061562 | LESCOL 20MG | NOVARTIS PHARMACEUTICALS CANADA INC | Capsule | FLUVASTATIN (FLUVASTATIN SODIUM) 20 MG | Cancelled Post Market |
| 02061570 | LESCOL 40MG | NOVARTIS PHARMACEUTICALS CANADA INC | Capsule | FLUVASTATIN (FLUVASTATIN SODIUM) 40 MG | Cancelled Post Market |
| 02400235 | SANDOZ FLUVASTATIN | SANDOZ CANADA INCORPORATED | Capsule | FLUVASTATIN (FLUVASTATIN SODIUM) 20 MG | Cancelled Post Market |
| 02400243 | SANDOZ FLUVASTATIN | SANDOZ CANADA INCORPORATED | Capsule | FLUVASTATIN (FLUVASTATIN SODIUM) 40 MG | Cancelled Post Market |
| 02492385 | SANDOZ FLUVASTATIN XL | SANDOZ CANADA INCORPORATED | Tablet (Extended-Release) | FLUVASTATIN (FLUVASTATIN SODIUM) 80 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 284 | 2004-03-22 | Supplement to a New Drug Submission (SNDS) | NEW DOSAGE FORM: 80 MG EXTENDED RELEASE TABLET |